Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers

Future Oncology

Volumn 9, Issue 9, 2013, Pages 1353-1364

  Bao, Yang Yang ^a   Zhou, Shui Hong ^a   Fan, Jun ^b   Wang, Qin Ying ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

anti tumor effect; apigenin; glucose uptake; GLUT 1; head and neck cancer; PI3K Akt pathway

Indexed keywords

APIGENIN; CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMININ; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUTATHIONE; IMATINIB; MESSENGER RNA; MITOXANTRONE; POLO LIKE KINASE 1; PROTEIN P21; PROTEIN P53; SONIC HEDGEHOG PROTEIN; SURVIVIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSFORMATION; ESOPHAGUS CANCER; GENE EXPRESSION; GLUCOSE TRANSPORT; HEAD AND NECK CANCER; HYPOXIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIMODALITY CANCER THERAPY; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APIGENIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84883296314     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.84     Document Type: Review

References (99)

1. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: Progress, potential and promise (review). Int. J. Oncol. 30(1), 233-245 (2007
2. Nangia-Makker P, Tait L, Shekhar MP et al. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int. J. Cancer 121(4), 884-894 (2007
3. Verbeek R, van Tol EA, van Noort JM. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Biochem. Pharmacol. 70(2), 220-228 (2005
4. Wang J, Liao Y, Fan J, Ye T, Sun X, Dong S. Apigenin inhibits the expression of IL-6, IL-8, and ICAM-1 in DEHP-stimulated human umbilical vein endothelial cells and in vivo. Inflammation 35(4), 1466-1476 (2012
5. Liu R, Zhang T, Yang H, Lan X, Ying J, Du G. The flavonoid apigenin protects brain neurovascular coupling against amyloid-β25-35-induced toxicity in mice. J. Alzheimers Dis. 24(1), 85-100 (2011
6. Si D, Wang Y, Zhou YH et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug. Metab. Dispos. 37(3), 629-634 (2009
7. Tong X, Smith KA, Pelling JC. Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Mol. Carcinog. 51(3), 268-279 (2012
8. Zhao G, Qin GW, Wang J, Chu WJ, Guo LH. Functional activation of monoamine transporters by luteolin and apigenin isolated from the fruit of Perilla frutescens (L.). Britt. Neurochem. Int. 56(1), 168-176 (2010
9. Lee SW, Lee JT, Lee MG et al. In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells. J. Nat. Med. 63(2), 124-129 (2009
10. Taupin P. Apigenin and related compounds stimulate adult neurogenesis. Mars, Inc., the Salk Institute for Biological Studies: WO2008147483. Expert Opin. Ther. Pat. 19(4), 523-527 (2009
11. Lefort ÉC, Blay J. The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells. Clin. Exp. Metastasis 28(4), 337-349 (2011
12. Chen V, Staub RE, Baggett S et al. Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle. PLoS One 7(1), e30107 (2012
13. Shukla S, Maclennan GT, Fu P, Gupta S. Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharm. Res. 29(6), 1506-1517 (2012
14. Seo YJ, Kim BS, Chun SY, Park YK, Kang KS, Kwon TG. Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. J. Korean Med. Sci. 26(11), 1489-1494 (2011
15. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S. Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study. Mol. Carcinog. 51(12), 952-962 (2012
16. Nagaprashantha LD, Vatsyayan R, Singhal J et al. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem. Pharmacol. 82(9), 1100-1109 (2011
17. Shukla S, Gupta S. Apigenin: A promising molecule for cancer prevention. Pharm. Res. 27(6), 962-978(2010
18. Wong IL, Chan KF, Tsang KH et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J. Med. Chem. 52(17), 5311-5322 (2009
19. Li ZD, Hu XW, Wang YT, Fang J. Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett. 583(12), 1999-2003 (2009
20. Luo H, Jiang BH, King SM, Chen YC. Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr. Cancer 60(6), 800-809 (2008
21. Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis 29(12), 2369-2376 (2008
22. Fang J, Zhou Q, Liu LZ et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28(4), 858-864 (2007
23. Liu Q, Chen X, Yang G, Min X, Deng M. Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells. Biocell 35(3), 71-79 (2011
24. Kilani-Jaziri S, Frachet V, Bhouri W, Ghedira K, Chekir-Ghedira L, Ronot X. Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis. Drug. Chem. Toxicol. 35(1), 1-10 (2012
25. Lefort ÉC, Blay J. Apigenin and its impact on gastrointestinal cancers. Mol. Nutr. Food Res. 57(1), 126-144 (2013
26. Turktekin M, Konac E, Onen HI, Alp E, Yilmaz A, Menevse S. Evaluation of the effects of the flavonoid apigenin on apoptotic pathway gene expression on the colon cancer cell line (HT29). J. Med. Food 14(10), 1107-1117 (2011
27. Zhong Y, Krisanapun C, Lee SH et al. Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53. Eur. J. Cancer 46(18), 3365-3374 (2010
28. Leonardi T, Vanamala J, Taddeo SS et al. Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp. Biol. Med (Maywood) 235(6), 710-717 (2010
29. Chan LP, Chou TH, Ding HY et al. Apigenin induces apoptosis via tumor necrosis factor receptor-and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim. Biophys. Acta 1820(7), 1081-1091 (2012
30. Masuelli L, Marzocchella L, Quaranta A et al. Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front. Biosci. 16, 1060-1068 (2011
31. Franek KJ, Zhou Z, Zhang WD, Chen WY. In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Int. J. Oncol. 26(1), 217-224 (2005
32. Warburg O. On the origin of cancer cells. Science 123(3191), 309-314 (1956
33. Nijsten MW, van Dam GM. Hypothesis: Using the Warburg effect against cancer by reducing glucose and providing lactate. Med. Hypotheses 73(1), 48-51 (2009
34. Wahl H, Daudi S, Kshirsagar M et al. Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol. Oncol. 116(1), 21-27 (2010
35. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur. J. Nucl. Med. Mol. Imaging 31(1), 5-12 (2004
36. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int. J. Oncol. 33(5), 1047-1054 (2008
37. Kobayashi M, Kaida H, Kawahara A et al. The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients. Clin. Nucl. Med. 37(5), 447-452 (2012
38. Han MW, Lee HJ, Cho KJ et al. Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck 34(10), 1395-1402 (2012
39. Li LF, Zhou SH, Zhao K et al. Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother. Radiopharm. 23(6), 701-714 (2008
40. Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J. Int. Med. Res. 38(6), 1885-1892 (2010
41. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1a, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 167 (2011
42. Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1 and -3 in the head and neck carcinoma -the correlation of the expression with the biological behaviors. ORL. J. Otorhinolaryngol. Relat. Spec. 70(3), 189-194 (2008
43. Kunkel M, Reichert TE, Benz P et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97(4), 1015-1024 (2003
44. Doki Y, Takachi K, Ishikawa O et al. Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy. Surgery 137(5), 536-544 (2005
45. Markowska J, Grabowski JP, Tomaszewska K et al. Significance of hypoxia in uterine cervical cancer. Multicentre study. Eur. J. Gynaecol. Oncol. 28(5), 386-388 (2007
46. Evans A, Bates V, Troy H et al. Glut-1 as a therapeutic target: Increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother. Pharmacol. 61(3), 377-393 (2008
47. Jensen RL. Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol. 92(3), 317-335 (2009
48. Zhou SH, Fan J, Chen XM, Chen KJ, Wang SQ. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 31(12), 1624-1633 (2009
49. Melstrom LG, Salabat MR, Ding XZ et al. Apigenin down-regulates the hypoxia response genes: HIF-1a, GLUT-1, and VEGF in human pancreatic cancer cells. J. Surg. Res. 167(2), 173-181 (2011
50. Melstrom LG, Salabat MR, Ding XZ et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 37(4), 426-431 (2008
51. Golkar L, Salaba MRt, Ujik MB et al. Apigenin inhibits pancreatic cancer cell proliferation via down-regulation of hypoxia inducible factor-1A (HIF-A) and the glucose transporter (GLUT-1) (Abstract). J. Surg. Res. 137(2), 191-192 (2007
52. Golkar L, Salabat MR, Ding XZ et al. Apigenin inhibits pancreatic cancer cell proliferation via down-regulation of the GLUT-1 glucose transporter through the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway (Abstract). Pancreas 33(4), 464 (2006
53. Hisanaga S, Endo R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J. Neurochem. 115(6), 1309-1321 (2010
54. Tsukahara T, Tanno Y, Watanabe Y. Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation. Nature 467(7316), 719-723 (2010
55. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6(9), 1102-1114 (2007
56. Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther. 5(4), 843-852 (2006
57. Ujiki MB, Ding XZ, Salabat MR et al. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 5, 76 (2006
58. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 14(16), 5000-5005 (2008
59. Seo HS, Ju JH, Jang K, Shin I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor α-negative breast cells. Nutr. Res. 31(2), 139-146 (2011
60. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int. J. Clin. Exp. Pathol. 4 (5), 444-453 (2011
61. Du JY, Xin Y. The effect of apigenin on cell cycle of ovarian carcinoma cell lines CAOV3. Zhong Guo Shi Yong Fu Ke He Chan Ke Za Zhi. 24(6), 456-458 (2008
62. Spella M, Kyrousi C, Kritikou E et al. Geminin regulates cortical progenitor proliferation and differentiation. Stem Cells 1269-1282 (2011
63. Pefani DE, Dimaki M, Spella M et al. Idas, a novel phylogenetically conserved geminin related protein, binds to geminin and is required for cell cycle progression. J. Biol. Chem. 286(26), 23234-23246 (2011
64. Salabat MR, Melstrom LG, Strouch MJ et al. Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin pancreatic cancer cell lines. Mol. Carcinog. 47(11), 835-844 (2008
65. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: From a prognostic foe to a predictive friend. Curr. Opin. Obstet. Gynecol. 19(1), 56-62 (2007
66. Way TD, Kao MC, Lin JK. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett. 579(1), 145-152 (2005
67. Shehata M, Schnabl S, Demirtas D et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 116(14), 2513-2521 (2010
68. Shukla S, Gupta S. Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study. Mol. Carcinog. 48(3), 243-252 (2009
69. Kaur P, Shukla S, Gupta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: An in vitro and in vivo study. Carcinogenesis 29(11), 2210-2217 (2008
70. Khan TH, Sultana S. Apigenin induces apoptosis in Hep G2 cells: Possible role of TNF-alpha and IFN-gamma. Toxicology 217(2-3),206-212 (2006
71. Shukla S, Gupta S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic. Biol. Med. 44(10), 1833-1845 (2008
72. Lu HF, Chie YJ, Yang MS et al. Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax and Bcl-2-triggered mitochondrial pathway. Int. J. Oncol. 36(6), 1477-1484 (2010
73. Lu HF, Chie YJ, Yang MS et al. Apigenin induces apoptosis in human lung cancer H460 cells through caspase-and mitochondria-dependent pathways. Hum. Exp. Toxicol. 30(8), 1053-1061 (2011
74. Choi EJ, Kim GH. 5-fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol. Rep. 22(6), 1533-1537 (2009
75. Ding J, Polier G, Köhler R, Giaisi M, Krammer PH, Li-Weber M. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J. Biol. Chem. 287(1), 641-649 (2012
76. Valdameri G, Trombetta-Lima M, Worfel PR et al. Involvement of catalase in the apoptotic mechanism induced by apigenin in HepG2 human hepatoma cells. Chem. Biol. Interact. 193(2), 180-189 (2011
77. Polier G, Ding J, Konkimalla BV et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2, e182 (2011
78. Lee SH, Ryu JK, Lee KY et al. Enhanced anti tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 259(1), 39-49 (2008
79. Zheng PW, Chiang LC, Lin CC. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 76(12), 1367-1379 (2005
80. King JC, Lu QY, Li G et al. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim. Biophys. Acta 1823(2), 593-604 (2012
81. Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc. Natl Acad. Sci. USA 105(44), 16958-11663 (2008
82. Mafuvadze B, Benakanakere I, Hyder SM. Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause 17(5), 1055-1063 (2010
83. Kim BR, Jeon YK, Nam MJ. A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti migration in human hepatocellular carcinoma cells. Food Chem. Toxicol. 49(7), 1626-1632 (2011
84. Slusarz A, Shenouda NS, Sakla MS et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 70(8), 3382-3390 (2010
85. Romanová D, Grancai D, Józová B, Bozek P, Vachálková A. Determination of apigenin in rat plasma by high-performance liquid chromatography. J. Chromatogr. A 870(1-2):463-467 (2000
86. Meyer H, Bolarinwa A, Wolfram G, Linseisen J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab. 50(3), 167-172 (2006
87. Cárdenas M, Marder M, Blank VC, Roguin LP. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg. Med. Chem. 14(9), 2966-2971 (2006
88. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 287(4), 914-920 (2001
89. Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H, Peppelenbosch MP. Cytotoxicity of apigenin on leukemia cell lines: Implications for prevention and therapy. Cell Death Dis. 1, e19 (2010
90. Zhang Q, Zhao XH, Wang ZJ. Flavones and flavonols exert cytotoxic effects on a human esophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem. Toxicol. 46(6), 2042-2053 (2008
91. Zhang Q, Zhao XH, Wang ZJ. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol. In vitro 23(5), 797-807 (2009
92. Yin F, Giuliano AE, Van Herle AJ. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res. 19(5B), 4297-4303 (1999
93. Schröder-van der Elst JP, Van der Heide D, Romijn JA, Smit JW. Differential effects of natural flavonoids on growth and iodide content in a human Na*/I-symporter-transfected follicular thyroid carcinoma cell line. Eur. J. Endocrinol. 150(4), 557-564 (2004
94. Jacobs SR, Herman CE, Maciver NJ et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180(7), 4476-4486 (2008
95. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276(12), 9519-9525 (2001
96. Korkeila E, Jaakkola PM, Pyrhönen S, Sundström J. Pronounced tumor regression after radiotherapy is associated with negative/ weak glucose transporter-1 expression in rectal cancer. Anticancer Res. 31(1), 311-315 (2011
97. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/-chemotherapy. BMC Cancer 5, 42 (2005
98. Kunkel M, Moergel M, Stockinger M et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 43(8), 796-803 (2007
99. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9(3), 288-296 (2008